echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The results showed that azacytidine combined with nafumab showed good response rate and overall survival rate in the treatment of AML

    The results showed that azacytidine combined with nafumab showed good response rate and overall survival rate in the treatment of AML

    • Last Update: 2018-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, published online in the Journal of cancer discovery, a phase II study from MD Anderson Cancer Center at the University of Texas showed that standard chemotherapy drugs (http://www.chemdrug.com/) The response rate and overall survival rate of azacytidine combined with an immunocheckpoint inhibitor, nafumab, in patients with relapsed or refractory acute myeloid leukemia (AML) are encouraging Study on the combination therapy of azacytidine and nevumab in this single arm study, a total of 70 patients with refractory / recurrent (R / R) AML received azacytidine 75mg / m2, D1-7, intravenous or subcutaneous injection and nevumab 3mg / kg, D1 and D14, intravenous injection every 4-6 weeks The overall response rate was 33% and 22% of the patients had complete remission The combination therapy of azacytidine and nevumab was particularly effective in patients who had not previously been treated with past methylated drugs (HMAS), such as azacytidine or dicithabine, with an overall response rate of 52% Despite the success of most patients in this study, 11% of the patients had grade 3-4 immune-related adverse events, and the total survival time of all patients was 6.3 months Phase III trial of azacytidine combined with nevumab as first-line treatment (http://www.chemdrug.com/sell/24/) Other ongoing studies using this combination therapy have been initiated, including: phase II randomized trials of azacytidine combined with or without PD-L1 inhibitors in the first-line treatment of elderly AML patients; and randomized trials of PD-1 inhibitors in the elimination of minimal residual diseases in high-risk AML patients Azacytidine has been approved in the United States and Europe for the treatment of myelodysplastic syndrome (MDS), and in Europe for the treatment of newly diagnosed acute myeloid leukemia (AML) in the elderly HMAS, such as azacytidine, play a role by increasing the expression of immunocheckpoint antibodies PD-1 and PD-L1 in AML and other tumors, promoting anti-tumor signals and inhibiting anti-tumor immunity.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.